FDA approves treatment for HIV-linked abdominal fat

Thu, 11/11/2010 - 9:35am
Mass High Tech: The Journal of New England Technology

The U.S. Food and Drug Administration has approved a treatment, developed by Canadian firm Theratechnologies and marketed exclusively in the U.S. by Rockland-based EMD Serono, for excess abdominal fat in HIV-infected patients with lipodystrophy.

The treatment, called EGRIFTA (tesamorelin for injection), is the only therapy for abdominal lipohypertrophy, according to a news release from EMD Serono. Tesamorelin is an analogue of the human growth hormone releasing factor. EGRIFTA’s long-term cardiovascular safety has not been studied, but two Phase 3 clinical trials have shown patients’ waist circumference and visceral adipose tissue were reduced in those taking EGRIFTA, as opposed to placebo. 



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.